NASDAQ:CERO CERo Therapeutics (CERO) Stock Price, News & Analysis $8.10 +0.10 (+1.25%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$8.02 -0.08 (-1.05%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CERo Therapeutics Stock (NASDAQ:CERO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CERo Therapeutics alerts:Sign Up Key Stats Today's Range$7.87▼$8.1750-Day Range$6.87▼$19.8352-Week Range$6.71▼$895.40Volume29,813 shsAverage Volume77,910 shsMarket Capitalization$3.16 millionP/E RatioN/ADividend YieldN/APrice Target$45.00Consensus RatingBuy Company Overview CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California. Read More CERo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreCERO MarketRank™: CERo Therapeutics scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingCERo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCERo Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about CERo Therapeutics' stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Read more about CERo Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.50% of the float of CERo Therapeutics has been sold short.Short Interest Ratio / Days to CoverCERo Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CERo Therapeutics has recently decreased by 46.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCERo Therapeutics does not currently pay a dividend.Dividend GrowthCERo Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.50% of the float of CERo Therapeutics has been sold short.Short Interest Ratio / Days to CoverCERo Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CERo Therapeutics has recently decreased by 46.73%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for CERo Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CERO on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added CERo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CERo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.72% of the stock of CERo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.64% of the stock of CERo Therapeutics is held by institutions.Read more about CERo Therapeutics' insider trading history. Receive CERO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CERo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CERO Stock News HeadlinesCERo Therapeutics (NASDAQ:CERO) Earns Buy Rating from D. Boral CapitalAugust 7 at 2:21 AM | americanbankingnews.comCERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236August 1, 2025 | finanznachrichten.deThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236July 31, 2025 | globenewswire.comCero Therapeutics files to sell 12.5M shares of common stock for holdersJuly 22, 2025 | msn.comInvivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical TrialJuly 7, 2025 | businesswire.comCero Therapeutics stock rating upgraded to Buy on solid tumor approachJune 24, 2025 | uk.investing.comCERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 | MorningstarJune 24, 2025 | morningstar.comMSee More Headlines CERO Stock Analysis - Frequently Asked Questions How have CERO shares performed this year? CERo Therapeutics' stock was trading at $120.00 at the start of the year. Since then, CERO stock has decreased by 93.3% and is now trading at $8.10. How were CERo Therapeutics' earnings last quarter? CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) posted its earnings results on Thursday, May, 15th. The company reported ($31.80) earnings per share (EPS) for the quarter. When did CERo Therapeutics' stock split? CERo Therapeutics's stock reverse split before market open on Friday, June 13th 2025.The 1-20 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of CERo Therapeutics? Shares of CERO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CERo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CERo Therapeutics investors own include Verve Therapeutics (VERV), Lithium Americas (LAC), NVIDIA (NVDA), Maxeon Solar Technologies (MAXN), ARM (ARM), AST SpaceMobile (ASTS) and BigBear.ai (BBAI). Company Calendar Last Earnings5/15/2025Today8/07/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CERO Previous SymbolNASDAQ:CERO CIK1870404 Webwww.cero.bio Phone215-731-9450FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Price Target for CERo Therapeutics$45.00 High Price Target$60.00 Low Price Target$30.00 Potential Upside/Downside+455.6%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.30 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-199.71% Debt Debt-to-Equity RatioN/A Current Ratio0.73 Quick Ratio0.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($41.98) per share Price / Book-0.19Miscellaneous Outstanding Shares390,000Free Float337,000Market Cap$3.16 million OptionableN/A Beta0.46 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:CERO) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.